Brain cancer vaccine trial halted: what we know

NCT ID NCT03382977

Terminated ⭐️ VACCINE ⭐️ Sponsor: VBI Vaccines Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a vaccine called VBI-1901 in 70 people with recurrent glioblastoma, an aggressive brain cancer. The goal was to find a safe dose and see if the vaccine could boost the immune system against the tumor. The trial was terminated early, so results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA MULTIFORME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma glioma susceptibility 1 neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA MULTIFORME

Contacts and locations

Show contact details

Locations

Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
MD Anderson Cancer Center

Houston, Texas, 77030, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Miami Cancer Institute

Miami, Florida, 33176, United States
Providence - Swedish Medical Center

Seattle, Washington, 98122, United States
Stanford

Stanford, California, 94305, United States
The Neurological Institute of New York Columbia University Medical Center

New York, New York, 10032, United States
The Valley Hospital - Neurosurgeons of New Jersey

Ridgewood, New Jersey, 07450, United States
University of California, Irvine

Irvine, California, 92868, United States
University of California, Los Angeles Neuro-Oncology Program

Los Angeles, California, 90095, United States
University of California, San Diego

La Jolla, California, 92093, United States
Vanderbilt University Medical Center

Nashville, Tennessee, 37232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.